key: cord-0972735-n4bzsoo8
authors: Rubel, Abdur Rahman; Chong, Pui Lin; Abdullah, Muhammad Syafiq; Asli, Rosmonaliza; Momin, Riamiza Natalie; Mani, Babu Ivan; Chong, Vui Heng
title: Lipemic serum in patients with Coronavirus Disease 2019 (COVID‐19) undergoing treatment
date: 2020-06-02
journal: J Med Virol
DOI: 10.1002/jmv.25942
sha: f2e995461b620c87faea6af5fc1a0b9557b6f011
doc_id: 972735
cord_uid: n4bzsoo8

We read with interest the article by Morrison et al. on acute hypertriglyceridemia secondary to tocilizumab in patients with severe COVID-19. (1) One patient also had pancreatitis, a dreaded complication of hypertriglyceridemia. Both patients were already on lopinavir/ritonavir before tocilizumab (added day 9 and day 13) was added. Propofol was briefly used. This article is protected by copyright. All rights reserved.

Both patients were already on lopinavir/ritonavir before tocilizumab (added day 9 and 13) was added. Propofol was briefly used.

We recently had two out of 47 patients with moderate/severe COVID-19 who were treated with lopinavir/ritonavir and developed significant hypertriglyceridemia resulting in lipemic serum. Lopinavir/ritonavir is known to be associated with lipid abnormality, 2,3 more so than tocilizumab. One study showed that at 12 weeks of treatment of lopinavir/ritonavir in patients with human immunodefieciency virus, small but significant increase from baseline in the fasting total cholesterol and triglyceride was observed. 2 Our patients developed lipemic serum within 2 weeks of treatment. In Morrison's cases, it is possible that the lopinavir/ ritonavir had contributed to or even caused the hypertriglyceridemia. Therefore it is important for clinicians to be aware and monitor for complications given that the COVID-19 pandemic will continue and these two medications continue to be used until better treatment options become available.

The authors declare that there are no conflict of interests.

F I G U R E 1 Lipemic serum as shown by a white pinkish top layer (between the arrows)

Letter to the Editor: acute hypertriglyceridemia in patients with COVID-19 receiving tocilizumab

Hyperlipidaemia in HIV-infected patients on lopinavir/ritonavir monotherapy in resource-limited settings

Lipid disorders in antiretroviralnaive patients treated with lopinavir/ritonavir-based HAART: frequency, characterization, and risk factors

Abdur Rahman Rubel 1